Genetic polymorphisms of MTHFR and aberrant promoter hypermethylation of the RASSF1A gene in bladder cancer risk in a chinese population

Journal of International Medical Research

Volumn 37, Issue 6, 2009, Pages 1882-1889

  Cai, D W ^a   Liu, X F ^a   Bu, R G ^a   Chen, X N ^a   Ning, L ^b   Cheng, Y ^a   Wu, Bin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Bladder cancer; Genetic polymorphisms; Methylation status; Methylenetetrahydrofolate reductase (MTHFR); Polymerase chain reaction (PCR); Ras association domain family 1A (RASSF1A)

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ACIDITY; ADULT; ARTICLE; BLADDER CANCER; CANCER PATIENT; CANCER RISK; CHINESE; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; METHYLATION; PH; POPULATION; PROMOTER REGION;

EID: 74949112351     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700625     Document Type: Article

References (26)

1. Parkin D, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin; 2008; 58: 71-96.
3. Hainaut P, Pfeifer G: Patterns of p53 G →T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001; 22: 367-374.
4. Wang M, Zhu H, Fu G, et al: Polymorphisms of methylenetetrahydrofolate reductase and methionine synthase genes and bladder cancer risk: a case-control study with meta-analysis. Clin Exp Med 2009; 9: 9-19.
5. Duthie S: Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull 1999; 55: 578-592.
6. Choi S, Mason J: Folate and carcinogenesis: an integrated scheme. J Nutr 2000; 130: 129-132.
7. Wei Q, Shen H, Wang L, et al: Association between low dietary folate intake and suboptimal cellular DNA repair capacity. Cancer Epidemiol Biomarkers Prev 2003; 12: 963-969.
8. Bailey L, Gregory JF 3rd: Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 1999; 129: 919-922.
9. Frosst P, Blom H, Milos R, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
10. Weisberg I, Tran P, Christensen B, et al: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.
11. Heijmans B, Boer J, Suchiman H, et al: A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. Cancer Res 2003; 63: 1249-1253.
12. Karagas M, Park S, Nelson H, et al: Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: a populationbased case-control study. Int J Hyg Environ Health 2005; 208: 321-327.
13. Kimura F, Florl A, Steinhoff C, et al: Polymorphic methyl group metabolism genes in patients with transitional cell carcinoma of the urinary bladder. Mutat Res 2001; 458: 49-54.
14. Lin J, Spitz M, Wang Y, et al: Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. Carcinogenesis 2004; 25: 1639-1647.
15. Moore L, Malats N, Rothman N, et al: Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. Int J Cancer 2007; 120: 2452-2458.
16. Paz M, Avila S, Fraga M, et al: Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 2002; 62: 4519-4524.
17. Li S, Rong M, Iacopetta B: Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer. Oncol Rep 2006; 15: 221-225.
18. Kang S, Kim J, Kang G, et al: Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 2005; 96: 173-180.
19. Lerman M, Minna J: The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000; 60: 6116-6133.
20. Catto J, Azzouzi A, Rehman I, et al: Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005; 23: 2903-2910.
21. Pfeifer G, Dammann R: Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc) 2005; 70: 576-583.
22. Liu X, Dai X, Wu B: Study of 5-Aza-CdR on transcription regulation of RASSF1A gene in the BIU87 cell line. Urol Int 2009; 82: 108-112.
23. Herman J, Graff J, Myöhänen S, et al: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
24. Moore LE, Wiencke JK, Bates MN, et al: Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina. Cancer Lett 2004; 211: 199-207.
25. Siraj A, Ibrahim M, Al-Rasheed M, et al: Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East. Ann Hematol 2007; 86: 887-895.
26. Lee M, Kim H, Byun D, et al: Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 2001; 61: 6688-6692.